201 related articles for article (PubMed ID: 12117459)
1. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position.
Ferdinand KC; Serrano CC; Ferdinand DP
Curr Hypertens Rep; 2002 Aug; 4(4):311-8. PubMed ID: 12117459
[TBL] [Abstract][Full Text] [Related]
2. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
[TBL] [Abstract][Full Text] [Related]
3. Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Pro position.
Cohn JN
Curr Hypertens Rep; 2002 Aug; 4(4):307-10. PubMed ID: 12117458
[TBL] [Abstract][Full Text] [Related]
4. Heart failure in African Americans: disparities can be overcome.
Sharma A; Colvin-Adams M; Yancy CW
Cleve Clin J Med; 2014 May; 81(5):301-11. PubMed ID: 24789589
[TBL] [Abstract][Full Text] [Related]
5. Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Colvin-Adams M; Taylor AL
Cleve Clin J Med; 2007 Mar; 74(3):227-34. PubMed ID: 17375804
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
Hammermeister KE; Fairclough D; Emsermann CB; Hamman R; Ho M; Phibbs S; Plomondon M; Valuck R; West D; Steiner JF
Clin Ther; 2009 Mar; 31(3):632-43. PubMed ID: 19393854
[TBL] [Abstract][Full Text] [Related]
7. The African American Heart Failure Trial: a clinical trial update.
Taylor AL
Am J Cardiol; 2005 Oct; 96(7B):44-8. PubMed ID: 16226935
[TBL] [Abstract][Full Text] [Related]
8. Racial differences in heart failure therapeutics.
Ishizawar D; Yancy C
Heart Fail Clin; 2010 Jan; 6(1):65-74. PubMed ID: 19945062
[TBL] [Abstract][Full Text] [Related]
9. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Carson P; Ziesche S; Johnson G; Cohn JN
J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of chronic heart failure.
Adorisio R; De Luca L; Rossi J; Gheorghiade M
Heart Fail Rev; 2006 Jun; 11(2):109-23. PubMed ID: 16937030
[TBL] [Abstract][Full Text] [Related]
11. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.
Jamerson KA
Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S24-30. PubMed ID: 10986156
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure.
Taylor JS; Ellis GR
Am J Cardiovasc Drugs; 2002; 2(6):389-99. PubMed ID: 14727954
[TBL] [Abstract][Full Text] [Related]
13. Heart failure management in African Americans: meeting the challenge.
Durand JB
J Clin Hypertens (Greenwich); 2004 Apr; 6(4 Suppl 1):42-7. PubMed ID: 15073466
[TBL] [Abstract][Full Text] [Related]
14. Is heart failure in African Americans a distinct entity?
Scott RL
Congest Heart Fail; 2003; 9(4):193-6. PubMed ID: 12937353
[TBL] [Abstract][Full Text] [Related]
15. BiDil: primary care physicians first and cardiologist when?
Matthews GE
J Natl Med Assoc; 2007 Jun; 99(6):697-9; quiz 700. PubMed ID: 17595944
[No Abstract] [Full Text] [Related]
16. Hypertension-related morbidity and mortality in African Americans--why we need to do better.
Ferdinand KC; Saunders E
J Clin Hypertens (Greenwich); 2006 Jan; 8(1 Suppl 1):21-30. PubMed ID: 16415637
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.
Klein L; O'Connor CM; Gattis WA; Zampino M; de Luca L; Vitarelli A; Fedele F; Gheorghiade M
Am J Cardiol; 2003 May; 91(9A):18F-40F. PubMed ID: 12729848
[TBL] [Abstract][Full Text] [Related]
18. The impact of race on response to RAAS inhibition.
Wallace TW; Drazner MH
Curr Heart Fail Rep; 2005 Aug; 2(2):72-7. PubMed ID: 16036054
[TBL] [Abstract][Full Text] [Related]
19. Congestive heart failure: what should be the initial therapy and why?
Chatterjee K
Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
[TBL] [Abstract][Full Text] [Related]
20. Introduction: heart failure in African Americans.
Yancy CW
Congest Heart Fail; 2004; 10(1):12. PubMed ID: 14872152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
